{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:53:38Z","timestamp":1790103218887,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2025ZD0548503"],"award-info":[{"award-number":["2025ZD0548503"]}]},{"name":"The Key Research and Development Program of Shaanxi","award":["2022ZDLSF01-04"],"award-info":[{"award-number":["2022ZDLSF01-04"]}]},{"name":"the Research of the Shaanxi Administration of Traditional Chinese Medicine","award":["2022-SLRH-LJ-009"],"award-info":[{"award-number":["2022-SLRH-LJ-009"]}]},{"name":"the Clinical Research Award of the First Affiliated Hospital of Xi'an Jiaotong University, China","award":["No. XJTU1AF-CRF-2023-006"],"award-info":[{"award-number":["No. XJTU1AF-CRF-2023-006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15656-5","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T14:33:18Z","timestamp":1769783598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of CD26 in breast cancer and its pan-cancer analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Runyi","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhuo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"15656_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175\u201396. https:\/\/doi.org\/10.1038\/s41573-018-0006-z.","journal-title":"Nat Rev Drug Discov"},{"key":"15656_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"key":"15656_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"key":"15656_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"key":"15656_CR5","doi-asserted-by":"publisher","unstructured":"Sun J-Y, Zhang D, Wu S, Xu M, Zhou X, Lu X-J, et al. Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res. 2020;8:35.\u00a0https:\/\/doi.org\/10.1186\/s40364-020-00212-5.","DOI":"10.1186\/s40364-020-00212-5"},{"key":"15656_CR6","doi-asserted-by":"publisher","unstructured":"Z. Aliyari Serej, A. Ebrahimi Kalan, A. Mehdipour, H. Nozad Charoudeh, Regulation and roles of CD26\/DPPIV in hematopoiesis and diseases, Biomed. Pharmacother. 2017;91:88\u201394. https:\/\/doi.org\/10.1016\/j.biopha.2017.04.060.","DOI":"10.1016\/j.biopha.2017.04.060"},{"key":"15656_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12781","volume":"185","author":"C Klemann","year":"2016","unstructured":"Klemann C, Wagner L, Stephan M, von H\u00f6rsten S. Cut to the chase: a review of CD26\/dipeptidyl peptidase-4\u2019s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185:1\u201321. https:\/\/doi.org\/10.1111\/cei.12781.","journal-title":"Clin Exp Immunol"},{"key":"15656_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1078\/0171-9335-00302","volume":"82","author":"E Boonacker","year":"2003","unstructured":"Boonacker E, Van Noorden CJF. The multifunctional or moonlighting protein CD26\/DPPIV. Eur J Cell Biol. 2003;82:53\u201373. https:\/\/doi.org\/10.1078\/0171-9335-00302.","journal-title":"Eur J Cell Biol"},{"key":"15656_CR9","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.3390\/molecules27144498","volume":"27","author":"X Hu","year":"2022","unstructured":"Hu X, Wang X, Xue X. Therapeutic perspectives of CD26 inhibitors in immune-mediated diseases. Molecules. 2022;27:4498. https:\/\/doi.org\/10.3390\/molecules27144498.","journal-title":"Molecules"},{"issue":"3","key":"15656_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/713609354","volume":"40","author":"AM Lambeir","year":"2003","unstructured":"Lambeir AM, Durinx C, Scharp\u00e9 S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40(3):209\u201394. https:\/\/doi.org\/10.1080\/713609354.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"15656_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100178","volume":"2","author":"K Nakagawa","year":"2021","unstructured":"Nakagawa K, Kijima T, Okada M, Morise M, Kato M, Hirano K, et al. Phase 2 study of YS110, a recombinant humanized anti-CD26 monoclonal antibody, in Japanese patients with advanced malignant pleural mesothelioma. JTO Clin Res Rep. 2021;2:100178. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100178.","journal-title":"JTO Clin Res Rep"},{"key":"15656_CR12","doi-asserted-by":"publisher","unstructured":"Zhang G, Liu B, Qiao D, Gao S, Zhu X, Huang J, He W, Gao R, Zhang L, Wang J, Huang Y, Gong Q. PROTAC-mediated structure-function disruption of CD26: a therapeutic strategy for driver-negative non-small cell lung cancer. EBioMedicine. 2025;122:106026. https:\/\/doi.org\/10.1016\/j.ebiom.2025.106026. Epub ahead of print. PMID: 41237665IF: 10.8 Q1 B1.","DOI":"10.1016\/j.ebiom.2025.106026"},{"key":"15656_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.624899","volume":"11","author":"L Shu","year":"2021","unstructured":"Shu L, Liu Y, Li J, Wu X, Li Y, Huang H. Landscape profiling analysis of DPP4 in malignancies: therapeutic implication for tumor patients with coronavirus disease 2019. Front Oncol. 2021;11:624899. https:\/\/doi.org\/10.3389\/fonc.2021.624899.","journal-title":"Front Oncol"},{"issue":"1","key":"15656_CR14","doi-asserted-by":"publisher","first-page":"2371051","DOI":"10.1080\/2162402X.2024.2371051","volume":"13","author":"O Franzese","year":"2024","unstructured":"Franzese O, Palermo B, Frisullo G, Panetta M, Campo G, D\u2019Andrea D, et al. ADA\/CD26 axis increases intra-tumor PD-1+CD28+CD8+ T-cell fitness and affects NSCLC prognosis and response to ICB. Oncoimmunology. 2024;13(1):2371051. https:\/\/doi.org\/10.1080\/2162402X.2024.2371051. PMID:38915783IF: 6.3 Q1 B2;PMCID:PMC11195478IF: 6.3 Q1 B2.","journal-title":"Oncoimmunology"},{"issue":"1","key":"15656_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11033-025-10235-6","volume":"52","author":"L Sun","year":"2025","unstructured":"Sun L, Ma Y, Geng C, Gao X, Li X, Ru Q, et al. DPP4, a potential tumor biomarker, and tumor therapeutic target: review. Mol Biol Rep. 2025;52(1):126. https:\/\/doi.org\/10.1007\/s11033-025-10235-6.","journal-title":"Mol Biol Rep"},{"key":"15656_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3892\/ijo.31.4.785","volume":"31","author":"J Stremenova","year":"2007","unstructured":"Stremenova J, Krepela E, Mares V, Trim J, Dbaly V, Marek J, et al. Expression and enzymatic activity of dipeptidyl peptidase-IV in human astrocytic tumours are associated with tumour grade. Int J Oncol. 2007;31:785\u201392. https:\/\/doi.org\/10.3892\/ijo.31.4.785.","journal-title":"Int J Oncol"},{"key":"15656_CR17","doi-asserted-by":"publisher","unstructured":"Ohnuma K, Hatano R, Komiya E, Otsuka H, Itoh T, Iwao N, et al. A novel role for CD26\/dipeptidyl peptidase IV as a therapeutic target. Front Biosci (Landmark Ed). 2018;23:1754\u201379.\u00a0https:\/\/doi.org\/10.2741\/4671.","DOI":"10.2741\/4671"},{"key":"15656_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031181","volume":"23","author":"L Ng","year":"2022","unstructured":"Ng L, Wong S-K, Huang Z, Lam C-S, Chow A-K, Foo D-C, et al. CD26 induces colorectal cancer angiogenesis and metastasis through CAV1\/MMP1 signaling. Int J Mol Sci. 2022;23:1181. https:\/\/doi.org\/10.3390\/ijms23031181.","journal-title":"Int J Mol Sci"},{"key":"15656_CR19","doi-asserted-by":"publisher","unstructured":"J.-H. Jang, F. Janker, I. De Meester, S. Arni, N. Borgeaud, Y. Yamada, I. Gil Bazo, W. Weder, W. Jungraithmayr, The CD26\/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity, Carcinogenesis. 2019;40:324\u2013334. https:\/\/doi.org\/10.1093\/carcin\/bgy146.","DOI":"10.1093\/carcin\/bgy146"},{"key":"15656_CR20","doi-asserted-by":"publisher","unstructured":"de Andrade CFCG, Bigni R, Pombo-de-Oliveira MS, Alves G, Pereira DA. CD26\/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia. J Enzyme Inhib Med Chem. 2009;24:708\u201314.\u00a0https:\/\/doi.org\/10.1080\/14756360802334800.","DOI":"10.1080\/14756360802334800"},{"key":"15656_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.leukres.2016.06.001","volume":"47","author":"M Matuszak","year":"2016","unstructured":"Matuszak M, Lewandowski K, Czy\u017c A, Kiernicka-Parulska J, Przyby\u0142owicz-Chalecka A, Jarmu\u017c-Szymczak M, et al. The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia. Leuk Res. 2016;47:166\u201371. https:\/\/doi.org\/10.1016\/j.leukres.2016.06.001.","journal-title":"Leuk Res"},{"key":"15656_CR22","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1600-0463.2008.01017.x","volume":"116","author":"MA Goscinski","year":"2008","unstructured":"Goscinski MA, Suo ZH, Nesland JM, Fl\u00f8renes VA, Giercksky K-E. Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines. APMIS. 2008;116:823\u201331. https:\/\/doi.org\/10.1111\/j.1600-0463.2008.01017.x.","journal-title":"APMIS"},{"key":"15656_CR23","doi-asserted-by":"publisher","unstructured":"V. Mare\u0161, J. Streme\u0148ov\u00e1, V. Lis\u00e1, H. Koz\u00e1kov\u00e1, J. Marek, M. Syr\u016f\u010dek, O. \u0160oula, A. \u0160edo, Compartment- and malignance-dependent up-regulation of \u03b3-glutamyltranspeptidase and dipeptidylpeptidase-IV activity in human brain gliomas, Histol. Histopathol. 2012;27:931\u2013940. https:\/\/doi.org\/10.14670\/HH-27.931.","DOI":"10.14670\/HH-27.931"},{"key":"15656_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-193","volume":"10","author":"A Varona","year":"2010","unstructured":"Varona A, Blanco L, Perez I, Gil J, Irazusta J, L\u00f3pez JI, et al. Expression and activity profiles of DPP IV\/CD26 and NEP\/CD10 glycoproteins in the human renal cancer are tumor-type dependent. BMC Cancer. 2010;10:193. https:\/\/doi.org\/10.1186\/1471-2407-10-193.","journal-title":"BMC Cancer"},{"key":"15656_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5181386","volume":"2022","author":"X Gao","year":"2022","unstructured":"Gao X, Le Y, Geng C, Jiang Z, Zhao G, Zhang P. DPP4 is a potential prognostic marker of thyroid carcinoma and a target for immunotherapy. Int J Endocrinol. 2022;2022:5181386. https:\/\/doi.org\/10.1155\/2022\/5181386.","journal-title":"Int J Endocrinol"},{"key":"15656_CR26","first-page":"848","volume":"30","author":"M Zhang","year":"2008","unstructured":"Zhang M, Qiao Y, Suo Z. Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma. Zhonghua Zhong Liu Za Zhi. 2008;30:848\u201352.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"15656_CR27","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1111\/bph.13248","volume":"172","author":"HJ Choi","year":"2015","unstructured":"Choi HJ, Kim JY, Lim S-C, Kim G, Yun HJ, Choi HS. Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression. Br J Pharmacol. 2015;172:5096\u2013109. https:\/\/doi.org\/10.1111\/bph.13248.","journal-title":"Br J Pharmacol"},{"key":"15656_CR28","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.exphem.2006.06.005","volume":"34","author":"BA Zabel","year":"2006","unstructured":"Zabel BA, Zuniga L, Ohyama T, Allen SJ, Cichy J, Handel TM, et al. Chemoattractants, extracellular proteases, and the integrated host defense response. Exp Hematol. 2006;34:1021\u201332. https:\/\/doi.org\/10.1016\/j.exphem.2006.06.005.","journal-title":"Exp Hematol"},{"key":"15656_CR29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.bbrc.2014.04.017","volume":"447","author":"E Komiya","year":"2014","unstructured":"Komiya E, Ohnuma K, Yamazaki H, Hatano R, Iwata S, Okamoto T, et al. CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells. Biochem Biophys Res Commun. 2014;447:609\u201315. https:\/\/doi.org\/10.1016\/j.bbrc.2014.04.017.","journal-title":"Biochem Biophys Res Commun"},{"key":"15656_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188356","volume":"1873","author":"B Piersma","year":"2020","unstructured":"Piersma B, Hayward M-K, Weaver VM. Fibrosis and cancer: a strained relationship. Biochim Biophys Acta Rev Cancer. 2020;1873:188356. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188356.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"15656_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3389\/fimmu.2015.00477","volume":"6","author":"J Zhong","year":"2015","unstructured":"Zhong J, Rajagopalan S. Dipeptidyl peptidase-4 regulation of SDF-1\/CXCR4 axis: implications for cardiovascular disease. Front Immunol. 2015;6:477. https:\/\/doi.org\/10.3389\/fimmu.2015.00477.","journal-title":"Front Immunol"},{"key":"15656_CR32","doi-asserted-by":"publisher","unstructured":"Bailey SR, Nelson MH, Majchrzak K, Bowers JS, Wyatt MM, Smith AS, et al. Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence. Nat Commun. 2017;8:1961.\u00a0https:\/\/doi.org\/10.1038\/s41467-017-01867-9.","DOI":"10.1038\/s41467-017-01867-9"},{"key":"15656_CR33","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","volume":"31","author":"P Armand","year":"2013","unstructured":"Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen Y-B, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199\u2013206. https:\/\/doi.org\/10.1200\/JCO.2012.48.3685.","journal-title":"J Clin Oncol"},{"key":"15656_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","volume":"17","author":"S Antonia","year":"2016","unstructured":"Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016;17:299\u2013308. https:\/\/doi.org\/10.1016\/S1470-2045(15)00544-6.","journal-title":"Lancet Oncol"},{"key":"15656_CR35","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nm.4321","volume":"23","author":"CH June","year":"2017","unstructured":"June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles\u2019 heel of cancer immunotherapy? Nat Med. 2017;23:540\u20137. https:\/\/doi.org\/10.1038\/nm.4321.","journal-title":"Nat Med"},{"key":"15656_CR36","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2:1346\u201353. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1051.","journal-title":"JAMA Oncol"},{"key":"15656_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709\u201317. https:\/\/doi.org\/10.1200\/JCO.2016.68.2005.","journal-title":"J Clin Oncol"},{"key":"15656_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13:195\u2013207. https:\/\/doi.org\/10.1038\/nrendo.2016.205.","journal-title":"Nat Rev Endocrinol"},{"key":"15656_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74\u201380. https:\/\/doi.org\/10.1126\/science.aaa6204.","journal-title":"Science"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15656-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15656-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15656-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:30:10Z","timestamp":1772620210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15656-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15656"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15656-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data from the HPA dataset and the TCGA program are publicly available, so we did not require informed patient consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}